{"filing":{"accession_number":"0001104659-26-087358","cik":"0002072188","ticker":"BIOT","company_name":"INSTINCT BIO TECHNICAL CO HOLDINGS INC.","form":"6-K","filing_date":"2026-07-28","report_date":"2026-07-28","primary_document":"tm2621475d1_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2072188/000110465926087358/tm2621475d1_6k.htm"},"events":[{"id":20969,"run_id":18892,"accession_number":"0001104659-26-087358","anchor_item_number":"EX-99.1","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Instinct Bio announced entry into an indicative term sheet for a proposed equity purchase facility allowing the company to sell up to $150 million of common stock over three years at VWAP-based pricing with a discount. This is a material dilutive equity issuance arrangement that would provide discretionary capital to the company, typical of PIPE-like or ATM-style offerings used by smaller biotechnology companies to raise cash. The $150 million size and three-year duration make this material to investors assessing capital structure and dilution risk.","company_name":"INSTINCT BIO TECHNICAL CO HOLDINGS INC.","ticker":"BIOT","filing_date":"2026-07-28","form":"6-K","submitted_at":null,"items":[{"id":20487,"accession_number":"0001104659-26-087358","item_number":"EX-99.1","item_title":"tm2621475d1_ex99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Instinct Bio announced entry into an indicative term sheet for a proposed equity purchase facility allowing the company to sell up to $150 million of common stock over three years at VWAP-based pricing with a discount. This is a material dilutive equity issuance arrangement that would provide discretionary capital to the company, typical of PIPE-like or ATM-style offerings used by smaller biotechnology companies to raise cash. The $150 million size and three-year duration make this material to investors assessing capital structure and dilution risk.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-28T13:26:37.736607+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":20487,"accession_number":"0001104659-26-087358","item_number":"EX-99.1","item_title":"tm2621475d1_ex99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Instinct Bio announced entry into an indicative term sheet for a proposed equity purchase facility allowing the company to sell up to $150 million of common stock over three years at VWAP-based pricing with a discount. This is a material dilutive equity issuance arrangement that would provide discretionary capital to the company, typical of PIPE-like or ATM-style offerings used by smaller biotechnology companies to raise cash. The $150 million size and three-year duration make this material to investors assessing capital structure and dilution risk.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-28T13:26:37.736607+00:00","company_name":"INSTINCT BIO TECHNICAL CO HOLDINGS INC.","ticker":"BIOT","filing_date":"2026-07-28"}]}